

# Noopur S Raje

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8648731/noopur-s-raje-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

334  
papers

9,901  
citations

48  
h-index

95  
g-index

364  
ext. papers

12,346  
ext. citations

4.8  
avg, IF

6.13  
L-index

#	Paper	IF	Citations
334	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. <i>Lancet Haematology</i> , <b>2022</b> , 9, e143-e161	14.6	6
333	Minimal residual disease in multiple myeloma: why, when, where. <i>Hematology American Society of Hematology Education Program</i> , <b>2021</b> , 2021, 37-45	3.1	2
332	Digital Health for Patients With Multiple Myeloma: An Unmet Need. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 1096-1105	5.2	1
331	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 3285-3293	4.4	
330	Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. <i>Blood</i> , <b>2021</b> ,	2.2	2
329	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 4082-4082	2.2	
328	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , <b>2021</b> , 138, 3801-3801	2.2	0
327	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 651-651	2.2	9
326	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , <b>2021</b> ,	2.2	6
325	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. <i>Blood</i> , <b>2021</b> , 138, 1655-1655	2.2	
324	Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 3839-3839	2.2	1
323	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 548-548	2.2	9
322	Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 5018-5018	2.2	0
321	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 3044-3044	2.2	1
320	KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2021</b> , 138, 4830-4830	2.2	0
319	Bone Marrow Adipocytes Induce Metabolic Reprogramming of Multiple Myeloma Cells. <i>Blood</i> , <b>2021</b> , 138, 1614-1614	2.2	
318	Mature Osteoblasts Are Critical Bone Marrow Niche Cells Regulating Multiple Myeloma Cell Growth, at Least in Part, By Affecting the Local Immune Microenvironment. <i>Blood</i> , <b>2021</b> , 138, 74-74	2.2	

317	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 4725-4725	2.2	
316	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , <b>2021</b> , 138, 4095-4095	2.2	
315	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , <b>2021</b> , 138, 1646-1646	2.2	0
314	A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 5043-5043	2.2	
313	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41). <i>Blood</i> , <b>2021</b> , 138, 4776-4776	2.2	0
312	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1582-1596	21.7	19
311	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , <b>2021</b> , 23, 1199-1211	23.4	1
310	Lifestyle considerations in multiple myeloma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 172	7	2
309	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e119-e130	21.7	33
308	How to Treat High-Risk Myeloma at Diagnosis and Relapse. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, 291-309	7.1	5
307	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e105-e118	21.7	32
306	Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8015-8015	2.2	2
305	Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8006-8006	2.2	12
304	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12082-12082	2.2	
303	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 3526-3533	10.7	5
302	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8036-8036	2.2	2
301	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8016-8016	2.2	8
300	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 10781552211015283	1.7	0

299	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 255-258	10.7	32
298	A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 226-233	7.1	2
297	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. <i>Blood Advances</i> , <b>2021</b> , 5, 367-376	7.8	5
296	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. <i>Blood Advances</i> , <b>2021</b> , 5, 725-736	7.8	7
295	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 705-716	59.2	287
294	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6432-6444	12.9	3
293	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. <i>Leukemia</i> , <b>2021</b> ,	10.7	10
292	Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 194	7	2
291	Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
290	regulates the action of nitrogen-containing bisphosphonates on bone. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	6
289	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , <b>2020</b> , 10, 657-664	6.3	46
288	Once-weekly (70 mg/m <sup>2</sup> ) vs twice-weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. <i>Cancer Medicine</i> , <b>2020</b> , 9, 2989-2996	4.8	9
287	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 5-14	2.3	13
286	How We Approach Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1119-1125	2.2	2
285	Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE) for Multiple Myeloma (MM) Digital Solution in Patients with MM. <i>Blood</i> , <b>2020</b> , 136, 3-4	2.2	0
284	A Novel in-Vivo Model to Examine Homing of Multiple Myeloma Cells in Postnatal, Inducible, and Reversible Loss of Mature Osteoblasts. <i>Blood</i> , <b>2020</b> , 136, 50-50	2.2	
283	Comparison of Denosumab Versus Intravenous (IV) Bisphosphonate Use for Hypercalcemia in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 14-16	2.2	
282	Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center. <i>Blood</i> , <b>2020</b> , 136, 13-13	2.2	

281	Multiple Myeloma Cells Induce Lipolysis in Adipocytes and Uptake Fatty Acids through Fatty Acid Transporter Proteins. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	
280	NCOR2 Mutations Are Associated with IMiD Resistance in Human Myeloma Cells. <i>Blood</i> , <b>2020</b> , 136, 4-4	2.2	
279	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	19
278	Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	8
277	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. <i>Blood</i> , <b>2020</b> , 136, 16-17	2.2	7
276	Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. <i>Blood</i> , <b>2020</b> , 136, 26-27	2.2	19
275	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	39
274	Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy. <i>Blood</i> , <b>2020</b> , 136, 3-4	2.2	6
273	Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 2-2	2.2	3
272	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8503-8503	2.2	68
271	A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8520-8520	2.2	
270	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1541-1554	12.9	35
269	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. <i>Leukemia</i> , <b>2020</b> , 34, 21-34	10.7	74
268	Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 724-735	2	2
267	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , <b>2020</b> , 136, 2513-2523	2.2	25
266	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , <b>2019</b> , 20, e302-e312	21.7	166
265	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4907-4916	12.9	25
264	Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in <i>Lancet Oncology</i> . <i>Dentistry Journal</i> , <b>2019</b> , 7,	3.1	3

263	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 794-802	7.1	8
262	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1726-1737	59.2	672
261	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 123-133	2.2	65
260	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1228-1263	2.2	104
259	Role of the RANK/RANKL Pathway in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 12-20	12.9	24
258	Updates and rationale of clinical trials in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , <b>2019</b> , 2, e59	1.2	
257	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	15
256	Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. <i>Cancer</i> , <b>2019</b> , 125, 3692-3698	6.4	25
255	Current management and emerging treatment strategies for multiple myeloma. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , <b>2019</b> , 60, 1243-1256	1.8	5
254	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2019</b> , 134, 1869-1869	2.2	27
253	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3169-3169	2.2	5
252	Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4328-4328	2.2	3
251	Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , <b>2019</b> , 134, 927-927	2.2	48
250	Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics. <i>Blood</i> , <b>2019</b> , 134, 606-606	2.2	9
249	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3178-3178	2.2	8
248	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8035-8035	2.2	3
247	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 1154-1165	7.3	73
246	Once-weekly (70 mg/m <sup>2</sup> ) versus twice-weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e19505-e19505	2.2	

245	Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18302-e18302	2.2	0
244	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. <i>Blood</i> , <b>2019</b> , 134, 3066-3066	2.2	0
243	Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4350-4350	2.2	
242	Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 316-316	2.2	
241	Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms. <i>Blood</i> , <b>2019</b> , 134, 1802-1802	2.2	1
240	Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4382-4382	2.2	0
239	Polyunsaturated Fatty Acid (PUFA) Signaling Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3108-3108	2.2	1
238	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. <i>Blood</i> , <b>2019</b> , 134, 3091-3091	2.2	
237	BCL2 blockade overcomes MCL1 resistance in multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 2098-2102	10.7	13
236	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 27	7	36
235	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3099-3108	15.1	123
234	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 478-486	12.9	19
233	Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. <i>Leukemia</i> , <b>2018</b> , 32, 1932-1947	10.7	59
232	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). <i>Haematologica</i> , <b>2018</b> , 103, e473-e479	6.6	11
231	Panobinostat and Multiple Myeloma in 2018. <i>Oncologist</i> , <b>2018</b> , 23, 516-517	5.7	32
230	Current developments in immunotherapy in the treatment of multiple myeloma. <i>Cancer</i> , <b>2018</b> , 124, 2075-2085	5.4	42
229	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 370-381	21.7	216
228	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , <b>2018</b> , 32, 1838-1841	10.7	24

227	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 525-536	2.4	14
226	Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. <i>Future Oncology</i> , <b>2018</b> , 14, 195-203	3.6	22
225	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 222-230	4.5	70
224	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e183267	13.4	45
223	A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3229-3229	2.2	21
222	Analysis of Hospitalization and Readmissions after CAR T Cell Therapy. <i>Blood</i> , <b>2018</b> , 132, 2301-2301	2.2	2
221	Patient Preferences for Multiple Myeloma (MM) Treatment: Interim Analysis of a Discrete Choice Experiment. <i>Blood</i> , <b>2018</b> , 132, 3586-3586	2.2	2
220	Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. <i>Blood</i> , <b>2018</b> , 132, 1969-1969	2.2	8
219	The Pleiotropic Immunosuppressive Role of Osteoclasts in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4447-4447	2.2	1
218	Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. <i>Blood</i> , <b>2018</b> , 132, 488-488	2.2	55
217	Mature Osteoblasts Provide a Protective Niche Against Multiple Myeloma Growth and Survival within the Tumor Microenvironment. <i>Blood</i> , <b>2018</b> , 132, 4476-4476	2.2	2
216	Arachidonic Acid Induces Ferroptosis-Mediated Cell-Death in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4498-4498	2.2	4
215	bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8007-8007	2.2	45
214	A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8012-8012	2.2	4
213	Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8022-8022	2.2	1
212	Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8024-8024	2.2	5
211	Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8038-8038	2.2	4
210	A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS3103-TPS3103	2.2	6



209	Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15062-e15062	2.2	
208	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). <i>Blood</i> , <b>2018</b> , 132, 5664-5664	2.2	
207	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. <i>Blood</i> , <b>2018</b> , 132, 3253-3253	2.2	
206	Overcoming MCL1 Resistance in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 472-472	2.2	
205	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , <b>2018</b> , 4, 384-388	13.4	191
204	Treatment of Patients in First or Second Relapse <b>2018</b> , 77-102		
203	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2755-2761	2.2	91
202	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 812-818	2.2	69
201	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	14
200	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1949-1968	4.8	32
199	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 231-244	4.5	23
198	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3307-3315	12.9	148
197	Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2017</b> , 33, 15-21	0.7	9
196	New monoclonal antibodies on the horizon in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , <b>2017</b> , 8, 41-53	5.7	13
195	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 230-269	7.3	142
194	Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 783-795	4.5	30
193	Myeloma and Bone Disease. <i>Current Osteoporosis Reports</i> , <b>2017</b> , 15, 483-498	5.4	35
192	Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , <b>2017</b> , 130, 740-740	2.2	58

191	Psychosocial effects of the relaxation response resiliency program (SMART-3RP) in patients with MGUS and smoldering multiple myeloma: A waitlist controlled randomized clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10051-10051	2.2	4
190	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2004-2004	2.2	1
189	First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3010-3010	2.2	31
188	Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8005-8005	2.2	7
187	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9074-9074	2.2	9
186	Myeloma bone disease: pathogenesis and treatment. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 285-295	0.6	15
185	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1569-1578	21.7	133
184	Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 363ra147	17.5	93
183	Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1378-84	12.9	32
182	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , <b>2016</b> , 7, 10258	17.4	61
181	Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies. <i>Blood</i> , <b>2016</b> , 128, 2110-2110	2.2	17
180	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2122-2122	2.2	1
179	Preliminary Results from a Phase 1b Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2123-2123	2.2	19
178	Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , <b>2016</b> , 128, 2124-2124	2.2	2
177	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , <b>2016</b> , 128, 3307-3307	2.2	15
176	Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 3320-3320	2.2	1
175	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , <b>2016</b> , 128, 480-480	2.2	3
174	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , <b>2016</b> , 128, 675-675	2.2	34

173	the Use of Tailored Feedback to Improve Hematologist Competence and Clinical Decision Making for the Treatment of Patients with Multiple Myeloma: a Novel Web-Based Educational Solution. <i>Blood</i> , <b>2016</b> , 128, 3570-3570	2.2	
172	Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution. <i>Blood</i> , <b>2016</b> , 128, 800-800	2.2	
171	Effect of the Wnt-Signaling Inhibitor Sclerostin and Bone Marrow Adipocytes on Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2077-2077	2.2	
170	Identification and Validation of HLA-A24 XBP1 <sup>us</sup> , XBP1 <sup>sp</sup> , CD138, and CS1 Peptides to Generate Antigen Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. <i>Blood</i> , <b>2016</b> , 128, 5689-5689	2.2	
169	Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1225-34	6.3	72
168	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 495-503	3.1	6
167	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 389-400	7.3	44
166	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. <i>Blood</i> , <b>2016</b> , 127, 2355-6	2.2	11
165	Bone Disease in Multiple Myeloma. <i>Cancer Treatment and Research</i> , <b>2016</b> , 169, 251-270	3.5	18
164	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5688-5695	12.9	17
163	Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 657-64	2.2	262
162	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4607-18	12.9	214
161	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 843-50	4.5	42
160	Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 788-800	5.5	81
159	Role of decorin in multiple myeloma (MM) bone marrow microenvironment. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 465-70	6.3	15
158	Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1161-71	12.9	77
157	Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. <i>Cell Reports</i> , <b>2015</b> , 10, 755-770	10.6	18
156	Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma. <i>EBioMedicine</i> , <b>2015</b> , 2, 71-3	8.8	10

155	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , <b>2015</b> , 126, 1827-1827	2.2	10
154	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , <b>2015</b> , 126, 3036-3036	2.2	10
153	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD <sup>®</sup> ) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , <b>2015</b> , 126, 3040-3040 <sup>2</sup>	2.2	15
152	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). <i>Blood</i> , <b>2015</b> , 126, 3055-3055	2.2	5
151	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4217-4217	2.2	7
150	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). <i>Blood</i> , <b>2015</b> , 126, 4228-4228	2.2	17
149	Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4241-4241 <sup>2</sup>	2.2	5
148	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , <b>2015</b> , 126, 4246-4246	2.2	2
147	Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4255-4255	2.2	10
146	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , <b>2015</b> , 126, 4263-4263	2.2	9
145	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). <i>Blood</i> , <b>2015</b> , 126, 728-728	2.2	9
144	New Clinical and Research Directions in Myeloma-Related Bone Disease <b>2015</b> , 12,		1
143	Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8510-8510	2.2	7
142	A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8612-8612 <sup>2</sup>	2.2	1
141	Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS8611-TPS8611	2.2	
140	Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8579-8579	2.2	1
139	Novel In Vivo Model of Multiple Myeloma Bone Disease Using Tricalcium Phosphate Artificial Bone Grafts. <i>Blood</i> , <b>2015</b> , 126, 4200-4200	2.2	
138	The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival. <i>Blood</i> , <b>2015</b> , 126, 3633-3633	2.2	

137	The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy. <i>Blood</i> , <b>2015</b> , 126, 2992-2992	2.2	
136	Early Mortality in Newly Diagnosed Multiple Myeloma in the Context of Novel Drugs. <i>Blood</i> , <b>2015</b> , 126, 3315-3315	2.2	1
135	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 356-69	2	6
134	Advances in supportive care for multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 502-11	7.3	17
133	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , <b>2014</b> , 2, 1089-1108	1.1	
132	Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2489-500	6.1	21
131	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3955-61	12.9	27
130	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , <b>2014</b> , 124, 1715-1715	2.2	10
129	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 3454-3454	2.2	7
128	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , <b>2014</b> , 124, 4737-4737	2.2	3
127	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2014</b> , 124, 4764-4764	2.2	10
126	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 4772-4772	2.2	6
125	VE-BASKET, a first-in-kind, phase II, histology-independent Basket Study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2533-2533	2.2	8
124	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2512-2512	2.2	17
123	Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8534-8534	2.2	1
122	MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8589-8589	2.2	4
121	Clinical grade ?SNaPshot? genetic mutation profiling in multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19571-e19571	2.2	
120	A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8628-TPS8628	2.2	

119	Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8630-TPS8630	2.2	
118	Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 5726-5726	2.2	
117	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 27-27	2.2	1
116	A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBoRD) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2142-2142	2.2	
115	In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. <i>Bone</i> , <b>2013</b> , 53, 487-96	4.7	58
114	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2347-57	2.2	245
113	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , <b>2013</b> , 121, 2975-87	2.2	268
112	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , <b>2013</b> , 122, 1969-1969	2.2	11
111	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1976-1976	2.2	9
110	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial. <i>Blood</i> , <b>2013</b> , 122, 3190-3190	2.2	7
109	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , <b>2013</b> , 122, 759-759	2.2	14
108	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8584-8584	2.2	2
107	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8588-8588	2.2	0
106	Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8589-8589	2.2	1
105	Role Of Decorin In Multiple Myeloma (MM) Bone Marrow Microenvironment. <i>Blood</i> , <b>2013</b> , 122, 1851-1851	2.2	
104	A Novel Bruton's Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Impacts Multiple Myeloma Bone Microenvironment With Resultant Anti-Myeloma Activity. <i>Blood</i> , <b>2013</b> , 122, 682-682	2.2	1
103	Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , <b>2013</b> , 122, 3089-3089	2.2	0
102	Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1948-1948	2.2	1

101	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. <i>Blood</i> , <b>2012</b> , 119, 2579-89	2.2	458
100	Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. <i>Clinical Interventions in Aging</i> , <b>2012</b> , 7, 331-8	4	23
99	Cyclin dependent kinases in cancer: potential for therapeutic intervention. <i>Cancer Biology and Therapy</i> , <b>2012</b> , 13, 451-7	4.6	116
98	Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease. <i>Blood</i> , <b>2012</b> , 120, 328-328	2.2	1
97	Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. <i>Blood</i> , <b>2012</b> , 120, 4061-4061	2.2	11
96	Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study. <i>Blood</i> , <b>2012</b> , 120, 4077-4077	2.2	2
95	Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 447-447	2.2	6
94	Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 571-571	2.2	1
93	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , <b>2012</b> , 120, 565-565	2.2	
92	Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma. <i>Blood</i> , <b>2012</b> , 120, 3990-3990	2.2	
91	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. <i>Blood</i> , <b>2012</b> , 120, 3965-3965	2.2	
90	Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy. <i>Blood</i> , <b>2012</b> , 120, 1871-1871	2.2	
89	Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 4023-4023	2.2	
88	Increased Sclerostin Secretion in Multiple Myeloma Plays a Central Role in Osteolytic Bone Disease. <i>Blood</i> , <b>2012</b> , 120, 3989-3989	2.2	1
87	TEMPI: A Reversible Syndrome Following Treatment with Bortezomib. <i>Blood</i> , <b>2012</b> , 120, 986-986	2.2	1
86	AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 1822-1822	2.2	
85	Advances in the biology and treatment of bone disease in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1278-86	12.9	140
84	Bone anabolic agents for the treatment of multiple myeloma. <i>Cancer Microenvironment</i> , <b>2011</b> , 4, 339-49	6.1	19

83	The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. <i>Oncologist</i> , <b>2011</b> , 16, 651-62	5.7	47
82	Case records of the Massachusetts General Hospital: Case 29-2011: A 66-year-old woman with cardiac and renal failure. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1129-38	59.2	4
81	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4243-9	2.2	107
80	B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship. <i>Blood</i> , <b>2011</b> , 118, 1590-1590	2.2	4
79	Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis. <i>Blood</i> , <b>2011</b> , 118, 1819-1819	2.2	1
78	Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2912-2912	2.2	1
77	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , <b>2011</b> , 118, 3966-3966	2.2	1
76	Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2908-2908	2.2	1
75	Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2882-2882	2.2	
74	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , <b>2011</b> , 118, 815-815	2.2	
73	Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study. <i>Blood</i> , <b>2011</b> , 118, 5122-5122	2.2	
72	The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting. <i>Blood</i> , <b>2011</b> , 118, 1037-1037	2.2	
71	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , <b>2011</b> , 118, 1024-1024	2.2	
70	Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 128-128	2.2	
69	Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 5124-9	11.5	182
68	Novel bone-targeted strategies in oncology. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4084-93	12.9	35
67	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2010</b> , 116, 679-86	2.2	680
66	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. <i>Blood</i> , <b>2010</b> , 116, 1937-1937	2.2	1



65	Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study. <i>Blood</i> , <b>2010</b> , 116, 2971-2977	2.2	1
64	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). <i>Blood</i> , <b>2010</b> , 116, 2997-2997	2.2	1
63	CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies. <i>Blood</i> , <b>2010</b> , 116, 2999-2999	2.2	1
62	Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. <i>Blood</i> , <b>2010</b> , 116, 3049-3049	2.2	12
61	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , <b>2010</b> , 116, 3051-3051	2.2	3
60	Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale for a Novel Anti-Myeloma Strategy. <i>Blood</i> , <b>2010</b> , 116, 4075-4075	2.2	1
59	Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 1956-1956	2.2	
58	Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells. <i>Blood</i> , <b>2010</b> , 116, 791-791	2.2	1
57	AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity. <i>Blood</i> , <b>2010</b> , 116, 2994-2994	2.2	
56	Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 2996-2996	2.2	
55	Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 4042-4042	2.2	
54	Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. <i>Current Opinion in Molecular Therapeutics</i> , <b>2010</b> , 12, 586-97		58
53	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , <b>2009</b> , 114, 371-377	2.2	331
52	High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.. <i>Blood</i> , <b>2009</b> , 114, 1218-1218	2.2	2
51	Novel Three and Four Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , <b>2009</b> , 114, 127-127	2.2	11
50	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , <b>2009</b> , 114, 132-132	2.2	5
49	Molecular Profiling of Extramedullary and Medullary Plasmacytomas.. <i>Blood</i> , <b>2009</b> , 114, 1806-1806	2.2	1
48	Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Updated Phase I/II Trial Results.. <i>Blood</i> , <b>2009</b> , 114, 1869-1869	2.2	4

47	An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 3856-3856	2.2	4
46	NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells.. <i>Blood</i> , <b>2009</b> , 114, 3842-3842	2.2	
45	Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 1789-1789		
44	CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin.. <i>Blood</i> , <b>2009</b> , 114, 739-739	2.2	
43	AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.. <i>Blood</i> , <b>2009</b> , 114, 3833-3833	2.2	
42	Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma.. <i>Blood</i> , <b>2009</b> , 114, 4915-4915	2.2	
41	Use of Alkylating Agents Among Patients with Multiple Myeloma in a National Registry, 2006-2008.. <i>Blood</i> , <b>2009</b> , 114, 4941-4941	2.2	
40	Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. <i>Blood</i> , <b>2009</b> , 114, 295-295	2.2	
39	p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 598-606	4.5	46
38	Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2387-95	12.9	114
37	Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 491-504	15.9	183
36	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , <b>2008</b> ,		2
35	Treatment Patterns among Patients with Recently-Diagnosed Multiple Myeloma in a National Registry. <i>Blood</i> , <b>2008</b> , 112, 2374-2374	2.2	1
34	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 $\beta$ . <i>Blood</i> , <b>2008</b> , 112, 251-251	2.2	4
33	Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease. <i>Blood</i> , <b>2008</b> , 112, 2739-2739	2.2	3
32	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. <i>Blood</i> , <b>2008</b> , 112, 92-92	2.2	21
31	Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib. <i>Blood</i> , <b>2008</b> , 112, 2651-2651	2.2	
30	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , <b>2008</b> , 112, 2648-2648	2.2	

29	Molecular Profiling of Extramedullary and Medullary Plasmacytomas. <i>Blood</i> , <b>2008</b> , 112, 5111-5111	2.2	
28	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , <b>2008</b> , 112, 1716-1716	2.2	3
27	Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition. <i>Blood</i> , <b>2008</b> , 112, 3687-3687	2.2	
26	Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5903-9	12.9	116
25	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , <b>2007</b> , 110, 3744-52	2.2	132
24	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. <i>Blood</i> , <b>2007</b> , 110, 187-187	2.2	6
23	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.. <i>Blood</i> , <b>2007</b> , 110, 2714-2714	2.2	5
22	Attitudes toward Participation in Research, New Treatments, and Medication Side Effects among Multiple Myeloma and Myelodysplastic Syndrome Patients - The Patient Registries at Slone: Myeloma & MDS.. <i>Blood</i> , <b>2007</b> , 110, 3325-3325	2.2	
21	Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.. <i>Blood</i> , <b>2007</b> , 110, 4764-4764	2.2	
20	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , <b>2007</b> , 110, 1509-1509	2.2	1
19	Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 1239-47	3.5	21
18	Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , <b>2006</b> , 66, 6675-82	10.1	187
17	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , <b>2006</b> , 108, 3485-3485	2.2	2
16	Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3415-3415	2.2	
15	Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 3474-3474	2.2	
14	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. <i>Blood</i> , <b>2005</b> , 106, 1042-7	2.2	152
13	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 109-109	2.2	5
12	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , <b>2005</b> , 106, 3378-3378	2.2	1

11	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , <b>2005</b> , 106, 3380-3380	2.2	1
10	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , <b>2005</b> , 106, 627-627	2.2	
9	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. <i>British Journal of Haematology</i> , <b>2004</b> , 125, 343-52	4.5	64
8	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , <b>2004</b> , 104, 4188-93	2.2	167
7	SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. <i>Blood</i> , <b>2004</b> , 104, 3466-3466	2.2	
6	Bortezomib Targets Multiple Myeloma Endothelial Cells.. <i>Blood</i> , <b>2004</b> , 104, 4903-4903	2.2	
5	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. <i>Blood</i> , <b>2004</b> , 104, 764-764	2.2	
4	Thalidomide and immunomodulatory drugs as cancer therapy. <i>Current Opinion in Oncology</i> , <b>2002</b> , 14, 635-40	4.2	49
3	Multiple myeloma. <i>Current Treatment Options in Oncology</i> , <b>2000</b> , 1, 73-82	5.4	11
2	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2000</b> , 7, 126-32	2.7	7
1	RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. <i>Oncogene</i> , <b>1999</b> , 18, 6733-40	9.2	121